Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics
NCT ID: NCT02047058
Last Updated: 2014-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
240 participants
OBSERVATIONAL
2014-03-31
2017-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Nomogram for Predicting the Diagnosis of Central Malignant Tumors Based on Preoperative Clinical Characteristics and Laboratory Indicators:
NCT06914700
Prospective Real-World Study of Pathology AI for Glioma Molecular Prediction
NCT07263711
Supratotal Resection for Gliomas Within Noneloquent Areas
NCT02676687
Radiogenomic and Prognosis Analysis in Glioma
NCT04122521
Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
NCT05624736
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
proteomics, then these markers will be qualitatively and quantitatively evaluated in
glioblastoma patients by comparing their relationship with overrall
survival/progression-free survival and treatment response.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
high-risk
high-risk is determined by the evaluation of the biomarkers of Q cell.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Primary Glioblastoma is newly diagnosed and confirmed histologically
3. Patient is expected to be treated with temozolomide and followed up routinely at the study site.
4. Willing to sign the informed consent
Exclusion Criteria
2. History of any other malignancies
3. Refusal to give consent
4. No available tumor tissue for IDH analysis.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangzhou General Hospital of Guangzhou Military Command
OTHER
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
OTHER
First Affiliated Hospital of Fujian Medical University
OTHER
The First Affiliated Hospital of Nanchang University
OTHER
Capital Medical University
OTHER
Tianjin Medical University General Hospital
OTHER
Shenzhen Second People's Hospital
OTHER
Huashan Hospital
OTHER
West China Hospital
OTHER
Xiangya Hospital of Central South University
OTHER
The First Hospital of Jilin University
OTHER
First Hospital of China Medical University
OTHER
Qilu Hospital of Shandong University
OTHER
Second Affiliated Hospital of Soochow University
OTHER
Sun Yat-sen University
OTHER
Guangzhou First People's Hospital
OTHER
Xi'an Jiaotong University
OTHER
Southern Medical University, China
OTHER
Second Affiliated Hospital of Guangzhou Medical University
OTHER
Nanfang Hospital, Southern Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Songtao Qi, Doctor
Role: PRINCIPAL_INVESTIGATOR
Nanfang Glioma centre, Guangzhou, China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nanfang Glioma Centre
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z, LanXiao W, Fei Y. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 2012 Feb;103(2):269-73. doi: 10.1111/j.1349-7006.2011.02134.x. Epub 2011 Nov 28.
Qi ST, Yu L, Lu YT, Ou YH, Li ZY, Wu LX, Yao F. IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. Oncol Rep. 2011 Dec;26(6):1479-85. doi: 10.3892/or.2011.1428. Epub 2011 Aug 19.
Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tonjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Ryzhova M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Fruhwald MC, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, Durken M, Kulozik AE, Madden J, Donson A, Foreman NK, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C, Wiestler B, Wick W, Milde T, Witt O, Lindroth AM, Schwartzentruber J, Faury D, Fleming A, Zakrzewska M, Liberski PP, Zakrzewski K, Hauser P, Garami M, Klekner A, Bognar L, Morrissy S, Cavalli F, Taylor MD, van Sluis P, Koster J, Versteeg R, Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins VP, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N, Pfister SM. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012 Oct 16;22(4):425-37. doi: 10.1016/j.ccr.2012.08.024.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NFGC-001-MCP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.